Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis

MLA

Toshio Doi, et al. “Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis.” Pharmaceutical Research, vol. 22, Nov. 2005, pp. 2016–22. EBSCOhost, https://doi.org/10.1007/s11095-005-8383-5.

APA

Toshio Doi, Yuji Sakurai, Ken Ogasawara, Atsushi Fukatsu, Noriko Mori, Satohiro Masuda, Toshiya Katsura, Ken-ichi Inui, Hideyuki Motohashi, Tomohiro Terada, & Motokazu Matsuura. (2005). Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis. Pharmaceutical Research, 22, 2016–2022. https://doi.org/10.1007/s11095-005-8383-5

Chicago

Toshio Doi, Yuji Sakurai, Ken Ogasawara, Atsushi Fukatsu, Noriko Mori, Satohiro Masuda, Toshiya Katsura, et al. 2005. “Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis.” Pharmaceutical Research 22 (November): 2016–22. doi:10.1007/s11095-005-8383-5.